Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Saturday.

ALNY has been the topic of several other research reports. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Truist Financial began coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 target price on the stock. The Goldman Sachs Group lifted their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a "buy" rating in a research note on Tuesday, September 16th. Evercore ISI lifted their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an "outperform" rating in a research note on Thursday, September 11th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alnylam Pharmaceuticals in a research note on Saturday, September 27th. Twenty-four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $439.58.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ ALNY opened at $456.35 on Friday. The company has a market cap of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock's 50 day simple moving average is $441.57 and its 200 day simple moving average is $338.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In related news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the transaction, the director directly owned 775 shares in the company, valued at $362,390. The trade was a 95.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the transaction, the chief executive officer owned 65,409 shares in the company, valued at $29,568,138.45. The trade was a 12.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,144 shares of company stock worth $44,160,261. Corporate insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth $27,000. Bessemer Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $30,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $37,000. Finally, Ameritas Advisory Services LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $42,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.